Treat to Target in Axial Spondyloarthritis

Abstract

This article discusses treat-to-target strategies in axial spondyloarthritis and current status. Treatment ranging from nonsteroidal anti-inflammatory drugs to biologic and other disease-modifying drugs is discussed in the context of treat-to-target. The article explores evidence from landmark randomized, controlled trials and observational studies focusing on both radiographic and nonradiographic axial spondyloarthritis. The feasibility of treat-to-target, as well as predictors of remission are addressed in line with existing evidence. Finally, issues around management principles and challenges, as well as unmet need in the field, are highlighted.

Keywords: Axial spondyloarthritis; Biologic DMARDs; Nonradiographic axSpA; Radiographic axSpA; TNF inhibitors; Treat to target; axSpA.